The report highlights Emcure's domestic formulations growth of 19.3% YoY outperforming the IPM and assigns a BUY rating with 33% upside to target.
Read this note →Emcure Pharmaceuticals Limited
NSE EMCURE BSE 544210 INE168P01015
0 filings · 0 analysed
2,215.00
+1.88%
over 5 days
Prices from Yahoo Finance, NSE close, delayed — indicative only, not for dealing.
Targets, and what happened next
What each house published, and where the price has gone since. Orivam issues no calls of its own and takes no view on these.
| House | Published | Call | Entry | Target | Now | Progress | Standing |
|---|---|---|---|---|---|---|---|
| Motilal Oswal Financial Services Ltd. (MOFSL) | 07 Oct 2026, 08:43 | long | 1,918.00 | 2,330.00 | 2,212.80 | 72% | open by 2027-10-07 |
| Motilal Oswal Financial Services Ltd. | 28 Sep 2026, 08:45 | long | 1,927.80 | 2,300.00 | 2,212.80 | 77% | open by 2027-09-28 |
| Motilal Oswal Financial Services Ltd. (MOFSL) | 23 Sep 2026, 08:47 | long | 1,981.70 | 2,300.00 | 2,212.80 | 73% | open by 2027-09-23 |
Deadlines: 0 stated by the house, the rest set by Orivam’s convention — ten trading days for a technical call, twelve months for a price target. A target with no date cannot be judged, so one has to be chosen.
What the desks said
The report states Emcure Pharmaceuticals approved the merger of its subsidiaries Zuventus Healthcare and Emcutix Biopharmaceuticals into the parent company as part of corporate restructuring.
Read this note →Listed among one-year focus investment ideas at CMP Rs 1,927 with 20% upside.
Read this note →The report lists Emcure Pharma as a Focus Investment Idea with a Buy rating, CMP Rs 1,937 and target Rs 2,300, implying 19% upside over 1 year.
Read this note →Listed in the Focus Investment Ideas table with CMP Rs 1,937 and 19% upside.
Read this note →Listed among focus investment ideas with 18% stated upside.
Read this note →The report cites Emcure as expected to deliver 21%/32% YoY growth in EBITDA/PAT due to superior execution, and lists it as one of the report's top ideas.
Read this note →The report lists Emcure Pharma as a Focus Investment Idea with a Buy rating, CMP Rs 1,943 and target Rs 2,300, implying 18% upside.
Read this note →The Focus Investment Ideas list shows Emcure Pharma rated Buy at CMP 1972 with a target of 2,300 (17% upside).
Read this note →The report lists Emcure Pharma as a focus investment idea with a Buy rating and target of Rs 2,300 (19% upside).
Read this note →The report lists Emcure Pharma as a focus investment idea with a Buy rating and 17% upside target.
Read this note →The note lists Emcure Pharma as a Focus Investment Idea with a BUY rating and target of Rs 2300.
Read this note →Announcement timeline
No filings stored for this company yet.
Never miss the next one.
Orivam emails what the research desks published each trading morning, attributed and linked to the original notes. Free.
Get the daily brief